Faculty of Medicine, Department of Cardiovascular Surgery, Semmelweis University, Budapest, Hungary.
Free Radic Res. 2011 Oct;45(10):1115-23. doi: 10.3109/10715762.2011.602074. Epub 2011 Jul 15.
In 1996, a novel oxidative stress biomarker, referred to as advanced oxidation protein products (AOPP), was detected in the plasma of chronic uremic patients. It was suggested that AOPP measure highly oxidized proteins, especially albumin. Recent data in turn appear to indicate that oxidized fibrinogen is the key molecule responsible for the AOPP reaction in the human plasma. Since fibrinogen is an acute-phase reactant, it is evident that during each episode of inflammatory response, the antioxidant capacity of the plasma is enhanced. In this context, fibrinogen can be regarded as a component of the antioxidant system of the plasma proteome. It was also demonstrated that oxidized fibrinogen is bound to apolipoprotein(a) of lipoprotein(a) via lysine binding sites. Thus, apo(a) could compete with plasminogen (and/or tissue plasminogen activator) for its binding sites of fibrin(ogen), causing inhibition of fibrinolysis, and thereby promote atherosclerosis and cardiovascular disease.
1996 年，在慢性尿毒症患者的血浆中检测到一种新型的氧化应激生物标志物，称为晚期氧化蛋白产物（AOPP）。有人认为 AOPP 衡量的是高度氧化的蛋白质，尤其是白蛋白。最近的数据又表明，氧化纤维蛋白原是导致人血浆中 AOPP 反应的关键分子。由于纤维蛋白原是急性期反应物，因此显然在每次炎症反应期间，血浆的抗氧化能力都会增强。在这种情况下，纤维蛋白原可以被视为血浆蛋白质组抗氧化系统的一个组成部分。还证明，氧化纤维蛋白原通过赖氨酸结合位点与脂蛋白(a)的载脂蛋白(a)结合。因此，载脂蛋白(a)可以与纤溶酶原（和/或组织纤溶酶原激活物）竞争其纤维蛋白（原）的结合位点，从而抑制纤维蛋白溶解，从而促进动脉粥样硬化和心血管疾病。
